Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
—
—
—
The Company offer various pharmaceutical formulations such as tablets, capsules, syrups, suspension and powders, focusing on segments such as ANTIBIOTICS, COUGH/COLD/ALLERGY, H-1RECEPTOR ANTAGONIST (ANTIULCERANT), NUTRACEUTICALS and NSAIDS
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
BIJOY HANS LTD. - 524723 - Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter/Six Months Ended 30Th September, 2024 | Download
BIJOY HANS LTD. - 524723 - Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter/Six Months Ended 30Th September, 2024 | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant